1161 related articles for article (PubMed ID: 8542938)
1. Hematopoietic growth factors after HLA-identical allogeneic bone marrow transplantation in patients treated with methotrexate-containing graft-vs.-host disease prophylaxis.
Martin-Algarra S; Bishop MR; Tarantolo S; Cowles MK; Reed E; Anderson JR; Vose JM; Bierman P; Armitage JO; Kessinger A
Exp Hematol; 1995 Dec; 23(14):1503-8. PubMed ID: 8542938
[TBL] [Abstract][Full Text] [Related]
2. Use of recombinant human granulocyte colony-stimulating factor in children given allogeneic bone marrow transplantation for acute or chronic leukemia.
Locatelli F; Pession A; Zecca M; Bonetti F; Prete L; Carrà AM; Prete A; Montagna D; Comoli P; Taibi RM; Paolucci G
Bone Marrow Transplant; 1996 Jan; 17(1):31-7. PubMed ID: 8673051
[TBL] [Abstract][Full Text] [Related]
3. Allogeneic peripheral blood stem cell transplantation in patients with early-phase hematologic malignancy: a retrospective comparison of short-term outcome with bone marrow transplantation.
Lemoli RM; Bandini G; Leopardi G; Rosti G; Bonini A; Fortuna A; Rondelli D; Mangianti S; Motta MR; Rizzi S; Tassi C; Cavo M; Remiddi C; Curti A; Conte R; Tura S
Haematologica; 1998 Jan; 83(1):48-55. PubMed ID: 9542323
[TBL] [Abstract][Full Text] [Related]
4. Different response to recombinant human granulocyte-macrophage colony-stimulating factor in primary and secondary graft failure after bone marrow transplantation.
Sierra J; Terol MJ; Urbano-Ispizua A; Rovira M; Marin P; Carreras E; Batlle M; Rozman C
Exp Hematol; 1994 Jul; 22(7):566-72. PubMed ID: 8013572
[TBL] [Abstract][Full Text] [Related]
5. Recombinant human granulocyte-macrophage colony-stimulating factor accelerates engraftment kinetics after allogeneic bone marrow transplantation for childhood acute lymphoblastic leukemia.
Madero L; Díaz MA; Ortega JJ; Olive T; Martínez A; Badell I; Muñoz A; Gómez P
Haematologica; 1999 Feb; 84(2):133-7. PubMed ID: 10091411
[TBL] [Abstract][Full Text] [Related]
6. Treatment with granulocyte colony-stimulating factor after allogeneic bone marrow transplantation for acute leukemia increases the risk of graft-versus-host disease and death: a study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
Ringdén O; Labopin M; Gorin NC; Le Blanc K; Rocha V; Gluckman E; Reiffers J; Arcese W; Vossen JM; Jouet JP; Cordonnier C; Frassoni F
J Clin Oncol; 2004 Feb; 22(3):416-23. PubMed ID: 14691124
[TBL] [Abstract][Full Text] [Related]
7. Unrelated donor bone marrow transplantation without T cell depletion using a chemotherapy only condition regimen. Low incidence of failed engraftment and severe acute GVHD.
Topolsky D; Crilley P; Styler MJ; Bulova S; Brodsky I; Marks DI
Bone Marrow Transplant; 1996 Apr; 17(4):549-54. PubMed ID: 8722353
[TBL] [Abstract][Full Text] [Related]
8. Allogeneic peripheral blood progenitor cell transplantation: analysis of short-term engraftment and acute GVHD incidence in 33 cases. allo-PBPCT Spanish Group.
Urbano-Ispizua A; Solano C; Brunet S; Hernández F; Sanz G; Alegre A; Petit J; Besalduch J; Vivancos P; Díaz MA; Moraleda JM; Carreras E; Ojeda E; de la Rubia J; Benet I; Domingo-Albós A; García-Conde J; Rozman C
Bone Marrow Transplant; 1996 Jul; 18(1):35-40. PubMed ID: 8831993
[TBL] [Abstract][Full Text] [Related]
9. Phase III randomized, double-blind placebo-controlled trial of rhGM-CSF following allogeneic bone marrow transplantation.
Nemunaitis J; Rosenfeld CS; Ash R; Freedman MH; Deeg HJ; Appelbaum F; Singer JW; Flomenberg N; Dalton W; Elfenbein GJ
Bone Marrow Transplant; 1995 Jun; 15(6):949-54. PubMed ID: 7581096
[TBL] [Abstract][Full Text] [Related]
10. Factors influencing the haematological recovery after allogeneic bone marrow transplantation in leukaemia patients treated with methotrexate-containing GVHD prophylaxis: a single-centre experience.
Hassan HT; Krog C; Stockschläder M; Schleimer B; Zeller W; Krüger W; Erttmann R; Zander AR
Anticancer Res; 1997; 17(1B):589-99. PubMed ID: 9066585
[TBL] [Abstract][Full Text] [Related]
11. CD6+ T cell depleted allogeneic bone marrow transplantation from genotypically HLA nonidentical related donors.
Soiffer RJ; Mauch P; Fairclough D; Alyea E; Anderson K; Fisher D; Freedman A; Bartlett-Pandite L; Robertson M; Schlossman R; Gollob J; Marcus K; Murray C; Kuhlman C; Freeman A; Nadler L; Ritz J
Biol Blood Marrow Transplant; 1997 Apr; 3(1):11-7. PubMed ID: 9209736
[TBL] [Abstract][Full Text] [Related]
12. Prognostic factors for long-term survival in leukemic marrow recipients with special emphasis on age and prophylaxis for graft-versus-host disease.
Aschan J; Ringdén O
Clin Transplant; 1994 Jun; 8(3 Pt 1):258-70. PubMed ID: 8061365
[TBL] [Abstract][Full Text] [Related]
13. Standard versus alternative myeloablative conditioning regimens in allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia.
Mengarelli A; Iori A; Guglielmi C; Romano A; Cerretti R; Torromeo C; Micozzi A; Fenu S; Laurenti L; Donato V; De Felice L; Arcese W
Haematologica; 2002 Jan; 87(1):52-8. PubMed ID: 11801465
[TBL] [Abstract][Full Text] [Related]
14. Recombinant human granulocyte colony-stimulating factor (rh-G-CSF) may accelerate hematopoietic recovery after HLA-identical sibling allogeneic peripheral blood stem cell transplantation.
Ozcan M; Ustün C; Akçağlayan E; Akan H; Arslan O; Ilhan O; Beksaç M; Gürman G; Demirer T; Arat M; Celebi H; Konuk N; Uysal A; Koç H
Bone Marrow Transplant; 2001 Mar; 27(5):499-505. PubMed ID: 11313683
[TBL] [Abstract][Full Text] [Related]
15. Recombinant human granulocyte colony-stimulating factor after allogeneic bone marrow transplantation.
Huang X; Guo N; Fan Y; Lu D
Chin Med J (Engl); 1996 Nov; 109(11):827-31. PubMed ID: 9275365
[TBL] [Abstract][Full Text] [Related]
16. Role of antithymocyte globulin and granulocyte-colony stimulating factor-mobilized bone marrow in allogeneic transplantation for patients with hematologic malignancies.
Chen XH; Zhang C; Zhang X; Gao L; Gao L; Kong PY; Peng XG; Qi DG; Sun AH; Zeng DF; Liu H; Gong Y; Wang QY
Biol Blood Marrow Transplant; 2009 Feb; 15(2):266-73. PubMed ID: 19167687
[TBL] [Abstract][Full Text] [Related]
17. The outcome of unrelated donor bone marrow transplantation in patients with hematologic malignancies using tacrolimus (FK506) and low dose methotrexate for graft-versus-host disease prophylaxis.
Devine SM; Geller RB; Lin LB; Dix SP; Holland HK; Maurer D; O'Toole K; Keller J; Connaghan DG; Heffner LT; Hillyer CD; Rodey GE; Winton EF; Maher RM; Fitzsimmons WE; Wingard JR
Biol Blood Marrow Transplant; 1997 Apr; 3(1):25-33. PubMed ID: 9209738
[TBL] [Abstract][Full Text] [Related]
18. Methotrexate vs Cyclosporin A as a single agent for graft-versus-host disease prophylaxis in pediatric patients with hematological malignancies undergoing allogeneic bone marrow transplantation from HLA-identical siblings: a single-center analysis in Japan.
Koga Y; Nagatoshi Y; Kawano Y; Okamura J
Bone Marrow Transplant; 2003 Jul; 32(2):171-6. PubMed ID: 12838282
[TBL] [Abstract][Full Text] [Related]
19. A pilot study of allogeneic bone marrow transplantation using related donors stimulated with G-CSF.
Isola LM; Scigliano E; Skerrett D; Shank B; Ross V; Najfeld V; Fruchtman S
Bone Marrow Transplant; 1997 Dec; 20(12):1033-7. PubMed ID: 9466275
[TBL] [Abstract][Full Text] [Related]
20. A retrospective comparison of allogeneic peripheral blood stem cell and bone marrow transplantation results from a single center: a focus on the incidence of graft-vs.-host disease and relapse.
Ustün C; Arslan O; Beksaç M; Koç H; Gürman G; Ozçelik T; Yilmaz B; Ilhan O; Akan H; Ozcan M; Demirer T; Uysal A; Konuk N; Arat M; Dilek I; Celebi H; Coskun HS
Biol Blood Marrow Transplant; 1999; 5(1):28-35. PubMed ID: 10232738
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
